The average one-year price target for TransMedics Group (BMV:TMDX) has been revised to MX$1,984.96 / share. This is an increase of 10.91% from the prior estimate of MX$1,789.78 dated September 13, ...

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to ...

Nearly €215B of French investment-grade corporate bonds yield less than comparable government debt amid sovereign concerns ...

While the proven Zacks Rank places an emphasis on earnings estimates and estimate revisions to find strong stocks, we also know that investors tend to develop their own individual strategies. With ...

The FDA has approved atezolizumab (Tecentriq) in combination with a fluoropyrimidine and oxaliplatin for the adjuvant treatment of adult and pediatric patients 2 years and older w ...

Paychex remains a Buy, trading at a 20%+ discount to fair value with robust fundamentals and a compelling dividend profile.

A Swiss real-world study of 38 palliative care patients found that rapid intravenous opioid titration reduced median pain scores from 8 to 2 within about eight minutes, with 90 percent of patients ...

Wealthy donors and companies can donate individual stocks to the new investment accounts for millions of children. That has ...

APLY offers 30% distribution yield but risks NAV erosion due to return of capital and limited upside participation in Apple ...

CSPC Pharma announced that the group has presented, in the form of a rapid oral presentation at the 2026 International ...

Chilean inflation cooled slightly more than expected in September, offering central bankers room to maintain their cautious stance on interest rates despite ongoing pressure from energy costs.

The state has limited how much money it gives to fast-growing school districts, creating million-dollar gaps between what is ...